Connect with us
DAPA Banner

Crypto World

Allogene Therapeutics (ALLO) Stock Soars 41% Following Breakthrough CAR T-Cell Trial Results

Published

on

ALLO Stock Card

Key Highlights

  • ALPHA3 trial demonstrated 58.3% MRD negativity in cema-cel patients compared to just 16.7% in the observation group
  • Zero instances of cytokine release syndrome or neurotoxicity reported among treated participants
  • Baird analysts upgraded their price target from $7.00 to $9.00 while maintaining Outperform status
  • Probability of success for the therapy program increased to 70% according to Baird’s assessment
  • Shares climbed to $3.87 from $2.91, marking approximately 99% gains year-to-date

Shares of Allogene Therapeutics experienced a dramatic rally exceeding 41% on April 13, 2026, following the disclosure of encouraging interim results from the company’s crucial Phase 2 ALPHA3 clinical study examining cemacabtagene ansegedleucel (cema-cel) in patients diagnosed with high-risk large B-cell lymphoma.


ALLO Stock Card
Allogene Therapeutics, Inc., ALLO

The released information originated from an interim futility analysis conducted on the trial. Within the initial cohort of 24 randomized participants, 58.3% receiving cema-cel treatment successfully achieved minimal residual disease (MRD) negativity. By contrast, the observation group saw merely 16.7% achieve this benchmark — representing a substantial 41.6 percentage point advantage.

Researchers are utilizing Natera’s investigational CLARITY MRD assay to detect high-risk patients prior to observable clinical relapse. The study positions cema-cel as a first-line consolidation treatment option, which would represent an earlier intervention point than most existing CAR T therapeutic strategies.

Remarkable Safety Results Generate Buzz

The trial’s safety outcomes proved equally compelling as the effectiveness data. Remarkably, no treated participants developed cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome — two complications frequently linked with CAR T cellular therapies.

Additionally, zero treatment-related serious adverse events were documented. Such a clean safety profile stands out significantly within this therapeutic category, prompting Baird analysts to highlight it as a key distinguishing characteristic when evaluating cema-cel against second-line autologous CAR T alternatives.

Advertisement

The therapy’s potential for outpatient administration, coupled with these favorable safety metrics, contributes to what could be a distinctive competitive position. Current CAR T treatments typically mandate inpatient care and are associated with more substantial toxicity concerns.

Following the data announcement, Baird elevated its ALLO price objective from $7.00 to $9.00 while retaining its Outperform recommendation. The investment firm also boosted its probability of success projection for this therapeutic program to 70%.

“The limited dataset size of 12 treated patients should generate enthusiasm,” Baird wrote, acknowledging the early-stage nature of the readout while flagging the initial results as a positive signal for the commercial profile in the first-line setting.

Looking Forward

The ALPHA3 clinical study is recruiting approximately 220 participants across more than 60 clinical sites. Efficacy endpoints continue to remain blinded currently, and the available dataset remains relatively limited. These preliminary figures will require validation as additional trial data matures.

Scheduled interim event-free survival analyses are anticipated in 2027, with complete primary results projected for 2028. Favorable outcomes from these assessments could potentially support a future biologics license application submission.

Advertisement

Additional Wall Street analysts are monitoring developments closely. Jefferies recently launched coverage on ALLO with a Buy recommendation and a $6.00 price objective, while Citizens maintained its Market Outperform stance with a $5.00 target price.

ALLO shares reached $3.87 on April 13, advancing from the previous session’s close of $2.91. The equity has gained approximately 99% year-to-date and is currently trading near its 52-week peak. InvestingPro analysis indicates the stock is presently valued above its calculated fair value, though the biotechnology company maintains a balance sheet with cash holdings exceeding debt obligations.

Source link

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Crypto World

Bitcoin Rally Above Range Highs Continues To Stall: Here’s Why

Published

on

Cryptocurrencies, Business, Bitcoin Price, Adoption, Markets, United States, Cryptocurrency Exchange, Price Analysis, Market Analysis, Bitcoin ETF, ETF

Establishing a strong Bitcoin (BTC) uptrend in 2026 remains a challenge, as exchange-traded fund (ETF) flows have shown limited growth since peaking above $60 billion in 2025.

At the same time, inflows to the gold ETF also dropped by nearly 25% in Q1 and the lack of a capital rotation into BTC signals muted institutional demand.

Bitcoin demand acceleration lacks pace

A recent report from Ecoinometrics shows a clear shift in the demand and persistence of Bitcoin exchange-traded fund (ETF) flows. Before the October 2025 price peak for BTC, ETF inflows often came in extended streaks, including a 15-day run of $4.4 billion in June 2025, which helped sustain upside momentum.

That consistency has faded in recent weeks. The recent direction of ETF flows has changed quickly, with inflow streaks lasting only a few days. Outflows have also clustered, reaching up to 10 consecutive days, totaling $3.2 billion in January, suggesting more reactive positioning.

Advertisement
Cryptocurrencies, Business, Bitcoin Price, Adoption, Markets, United States, Cryptocurrency Exchange, Price Analysis, Market Analysis, Bitcoin ETF, ETF
Bitcoin ETF flows comparison 2025 and 2026. Source: Ecoinometrics/X

The cumulative data reinforces this slowdown. Bitcoin ETF flows have plateaued at $55–$60 billion in 2026, showing little net growth. Over the same period, gold ETF flows dropped sharply to near $45 billion from around $60 billion, without a corresponding pickup in Bitcoin demand.

Cryptocurrencies, Business, Bitcoin Price, Adoption, Markets, United States, Cryptocurrency Exchange, Price Analysis, Market Analysis, Bitcoin ETF, ETF
Bitcoin, Gold ETF comparison. Source: Ecoinometrics/X

Ecoinometrics explained that the Federal Reserve’s lack of relief reinforces the slowdown in demand. US Treasury yields have shifted higher across maturities, with the 30-year yield rising toward 4.9% from 4.7% six months ago, while the shorter durations (10-year bond yield) also moved to 4.3% from 3.8% in October 2025. 

The elevated yields offer competitive returns, reducing the need for sustained ETF-driven exposure to Bitcoin. Ecoinometrics added,

“As long as the bond market holds this view, Bitcoin is operating without a liquidity tailwind. And without that tailwind, sustained upside becomes much harder to build.”

Cryptocurrencies, Business, Bitcoin Price, Adoption, Markets, United States, Cryptocurrency Exchange, Price Analysis, Market Analysis, Bitcoin ETF, ETF
US Treasury yield chart. Source: Ecoinometrics/X

Related: Bernstein says Bitcoin market already priced in quantum risk

Will Bitcoin overcome a key resistance level?

Crypto trader Ardi explained that one reason the current BTC range near $74,000 refuses to break is that retail and professional traders show similar behavior. Long positions drop as the price tests resistance, while the short exposure increases.

Hyblock’s four-hour chart highlights this repeated pattern. Long accounts decline sharply at highs, while short positioning builds at the same levels. These flows treat upward moves as opportunities to exit rather than extend exposure.

Cryptocurrencies, Business, Bitcoin Price, Adoption, Markets, United States, Cryptocurrency Exchange, Price Analysis, Market Analysis, Bitcoin ETF, ETF
BTC analysis by Ardi. Source: X

The profit-taking from longs meets fresh short entries in the order book. That interaction reinforces the upper boundary and interrupts attempts to retain the uptrend.

Ardi said that a shift would require stronger long-term accumulation near the resistance, where buyers absorb available supply rather than react to it. For now, the positioning data near $75,000 continues to cap each rally.

Advertisement

However, the above condition could soon change as early Bitcoin adopter Willy Woo noted the return of capital flows into BTC for the first time since January. In an X post, Woo said,

“Capital flows into BTC just flipped positive, first time since January. Liquidity is repairing… spot remains stable while derivatives after being destroyed 10 Oct is now making its second attempt at rebounding. 80k remains key test level.”

Related: Nigel Farage-backed Stack BTC adds $2.7M in Bitcoin to treasury